Skip to content

Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma

Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma - A Pilot Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07557563
Enrollment
10
Registered
2026-04-29
Start date
2026-06-01
Completion date
2028-03-31
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Tract Urothelial Carcinoma

Brief summary

It is a prospective single-arm pilot study to investigate the safety and feasibility of flexible ureteroscopy under local anaesthesia.

Detailed description

All consecutive patients who have undergone kidney-sparing surgery for managing upper tract urothelial carcinoma will be screened for study eligibility. Surveillance flexible ureteroscopy of the upper urinary tract under local anaesthesia in an ambulatory care setting. The peri-operative outcomes, patient reported outcomes, complication and cost-effectiveness analysis will be evaluated.

Interventions

Flexible ureterorenoscopy for Surveillance of UTUC under local anaesthesia

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Aged 18 years or older 2. Capable of giving informed consent 3. Having undergone an kidney-sparing surgery (endoscopic operation or segmental ureterectomy)

Exclusion criteria

1. Allergy to transurethral lidocaine jelly 2. On anticoagulation or anti-platelet medication with contraindications for cessation prior to the procedure 3. Structural abnormalities in the upper urinary tract on the intended side of examination

Design outcomes

Primary

MeasureTime frameDescription
Procedure success rateImmediately postoperativelyThe procedure is completed successfully.

Secondary

MeasureTime frameDescription
Complication rateOn day 30Assessed by Clavien Dindo Classification
Readmission rateOn Day 30Assessed by readmission to hospital after discharge

Countries

Hong Kong

Contacts

CONTACTHo Ming Chris WONG, MBChB
chriswong@surgery.cuhk.edu.hk35052625
PRINCIPAL_INVESTIGATORYuen Chun Jeremy TEOH, MD

Chinese University of Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026